Very interesting new #cancer study. Small data set but very encouraging.
Dr. Andrea Cercek, one of the lead researchers, said, “It’s absolutely incredible ... We’ve certainly never seen this before.”
All 12 patients experienced complete rectal cancer remission after receiving #Dostarlimab, a monoclonal antibody.
This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies.
The authors wrote:
“All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.”
Alchemike
npub106…2perc
2025-04-08 16:38:34
Author Public Key
npub1066yklzctwr34r0ph0hyteqjccg9q97ty7l0htm88jnq0kx425hs82percPublished at
2025-04-08 16:38:34Event JSON
{
"id": "e1fd148d1721df4b33711067afdbc0c8c6955c3edf722f5a1716f695d15ffd98",
"pubkey": "7eb44b7c585b871a8de1bbee45e412c6105017cb27befbaf673ca607d8d5552f",
"created_at": 1744130314,
"kind": 1,
"tags": [
[
"t",
"cancer"
],
[
"t",
"Dostarlimab"
],
[
"r",
"wss://eden.nostr.land/"
],
[
"r",
"wss://nos.lol/"
],
[
"r",
"wss://nostr-pub.wellorder.net/"
],
[
"r",
"wss://nostr.bitcoiner.social/"
],
[
"r",
"wss://nostr.wine/"
],
[
"r",
"wss://purplepag.es/"
],
[
"r",
"wss://lightningrelay.com/"
]
],
"content": "Very interesting new #cancer study. Small data set but very encouraging.\n\nDr. Andrea Cercek, one of the lead researchers, said, “It’s absolutely incredible ... We’ve certainly never seen this before.”\n\nAll 12 patients experienced complete rectal cancer remission after receiving #Dostarlimab, a monoclonal antibody.\n\nThis particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies.\n\nThe authors wrote:\n\n“All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.”\n\nhttps://m.primal.net/QIkE.mp4",
"sig": "a2e14196f3a2b02ba2f4f9f69837a753365dcfe1ac780673c33200ca15ff64cad1e085a884169fef581805224800e3d1abd9d53087a9397e8d34f454bafca1be"
}